Cargando…

Correction: Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420659/ https://www.ncbi.nlm.nih.gov/pubmed/34479928 http://dx.doi.org/10.1136/jitc-2021-003000corr1

Ejemplares similares

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
por: Hamdan, Firas, et al.
Publicado: (2021)

Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses
por: Hamdan, Firas, et al.
Publicado: (2023)

Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy
por: Zhao, Guo, et al.
Publicado: (2023)

Preclinical testing of oncolytic adenovirus sensitivity in patient-derived tumor organoids
por: Pascual-Sabater, Silvia, et al.
Publicado: (2021)

CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy
por: Li, Xiaofei, et al.
Publicado: (2022)

IGE AND IGGA ANTIBODY-MEDIATED RELEASE OF HISTAMINE FROM RAT PERITONEAL CELLS : II. INTERACTION OF IGGA AND IGE AT THE TARGET CELL
por: Bach, Michael K., et al.
Publicado: (1971)

A SIRPα‐Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer
por: Huang, Yao, et al.
Publicado: (2020)

The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors
por: Young, Brittany A., et al.
Publicado: (2013)

Oncolytic adenoviruses: A potent form of tumor immunovirotherapy
por: Cerullo, Vincenzo, et al.
Publicado: (2012)

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors
por: Gibson, Heather, et al.
Publicado: (2015)

Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells
por: Kilinc, Mehmet Okyay, et al.
Publicado: (2016)

A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth
por: Yoon, A-Rum, et al.
Publicado: (2015)

Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells
por: Czolk, Rebecca, et al.
Publicado: (2019)

Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses
por: Raimondi, Giulia, et al.
Publicado: (2020)

Calcium Influx Caused by ER Stress Inducers Enhances Oncolytic Adenovirus Enadenotucirev Replication and Killing through PKCα Activation
por: Taverner, William K., et al.
Publicado: (2019)

Transgenic viral expression of PH-20, IL-12, and sPD1-Fc enhances immune cell infiltration and anti-tumor efficacy of an oncolytic virus
por: Hong, Soon-Oh, et al.
Publicado: (2023)

HSF1 overexpression enhances oncolytic effect of replicative adenovirus
por: Wang, Cheng, et al.
Publicado: (2010)

An Infection-enhanced Oncolytic Adenovirus Secreting H. pylori Neutrophil-activating Protein with Therapeutic Effects on Neuroendocrine Tumors
por: Ramachandran, Mohanraj, et al.
Publicado: (2013)

Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers
por: Santos, Joao, et al.
Publicado: (2021)

Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy
por: Mahasa, Khaphetsi Joseph, et al.
Publicado: (2020)

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
por: Cervera-Carrascon, Victor, et al.
Publicado: (2020)

Afucosylated IgG Targets FcγRIV for Enhanced Tumor Therapy in Mice
por: Braster, Rens, et al.
Publicado: (2021)

Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and anti-tumor efficacy
por: Cherry, Tiffani, et al.
Publicado: (2010)

Oncolytic adenoviruses coated with MHC-I tumor epitopes for a new oncolytic vaccine platform
por: Capasso, Cristian, et al.
Publicado: (2015)

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
por: Santos, João Manuel, et al.
Publicado: (2020)

Late-phase miRNA-controlled oncolytic adenovirus for selective killing of cancer cells
por: Bofill-De Ros, Xavier, et al.
Publicado: (2015)

RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses
por: Shiina, M, et al.
Publicado: (2009)

Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment
por: Hirvinen, Mari, et al.
Publicado: (2013)

Strong antitumor efficacy of a pancreatic tumor‐targeting oncolytic adenovirus for neuroendocrine tumors
por: Yamamoto, Yuki, et al.
Publicado: (2017)

Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
por: Jung, Bo-Kyeong, et al.
Publicado: (2020)

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020)

Mining the Adenovirus Virome for Oncolytics Against Multiple Solid Tumor Types
por: Chen, Christopher Y., et al.
Publicado: (2011)

Self-assembly of X-shaped antibody to combine the activity of IgG and IgA for enhanced tumor killing
por: Liang, Yuexia, et al.
Publicado: (2022)

Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy
por: Zhou, Ping, et al.
Publicado: (2022)

Engineered bacterial outer membrane vesicles encapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy
por: Ban, Weiyue, et al.
Publicado: (2023)

Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control
por: Quixabeira, Dafne C. A., et al.
Publicado: (2021)

IgG Fc engineering to modulate antibody effector functions
por: Wang, Xinhua, et al.
Publicado: (2017)

The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models
por: Garcia-Moure, Marc, et al.
Publicado: (2019)

An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies
por: Ko, Sanghwan, et al.
Publicado: (2022)

Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG
por: Brandsma, Arianne M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p3cm04chmbls410nqkes7afgbv